Method for cell differentiation

Patent metadata

Field	Value
Publication number	US-9404086-B2
Application number	US-201414225740-A
Country	US
Kind code	B2
Filing date	Mar 26, 2014
Priority date	Mar 26, 2014
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The present invention relates to the field of cell biology, in particular to methods for differentiating pluripotent stem cells. The invention provides methods for differentiating primate pluripotent stem cells into cells of all three germinal layers. In particular, methods for differentiating primate pluripotent stem cells into the definitive endoderm are provided.

First claim

What is claimed is:

1. A method for producing definitive endoderm (DE) cells from primate pluripotent stem cells (pPSC) comprising culturing the pPSC in a medium comprising Activin A and a dimethyl sulfoxide (DMSO), thereby producing DE cells that express a gene selected from the group consisting of SOX17, CXCR4 and GATA4.

2. The method of claim 1 , wherein said Activin A is present in said medium at a concentration in a range from 50 ng/ml to 150 ng/ml.

3. The method of claim 2 , wherein the Activin A is present in the medium at a concentration of 100 ng/ml.

4. The method of claim 1 , wherein said pPSC are cultured in the presence of varying concentrations of said DMSO.

5. The method of claim 4 , wherein said DMSO is present in the medium at a concentration in a range from 0.25% to 2% volume/volume.

6. The method of claim 5 , wherein the DMSO is present in the medium at a concentration in the range from 0.25% to 0.75% volume/volume.

7. The method of claim 6 , wherein the DMSO is present in the medium at a concentration in the range from 0.5% to 0.6% volume/volume.

8. The method of claim 4 , wherein the pPSC are initially cultured in the presence of a high concentration of DMSO and then cultured in the presence of a low concentration of DMSO.

9. The method of claim 1 , wherein the medium additionally comprises one or more growth factors or modulators selected from the group consisting of FGF2, Wnt3a, SFRP5 and LY294002.

10. The method of claim 1 , wherein the pPSC are cultured in the medium for 3 to 5 days.

11. The method of claim 10 , wherein the pPSC are cultured in the medium for 4 days.

12. The method of claim 1 , wherein the pPSC are selected from the group consisting of human embryonic stem cells or human induced pluripotent stem cells.

Assignees

• Ge Healthcare Uk Ltd

Inventors

• Czysz Katarzyna Anna

Classifications

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• C12N2501/237

  Oncostatin M [OSM] · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• C12N2501/119

  Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 · CPC title

• C12N2501/39

  Steroid hormones · CPC title